文献速递脊柱关节炎

开发用于中轴型脊柱关节炎患者启动生物制剂或靶向合成改善病情抗风湿药的网络决策辅助工具

Development of a web-based decision aid for initiating biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in axial spondyloarthritis.
PubMed 文献 · RMD Open · 2023-01-01

本研究通过迭代过程,基于文献证据、患者和照护者的需求评估访谈以及荷兰风湿病学会脊柱关节炎工作组专家和荷兰关节炎协会患者信息专业人员的意见,系统开发了一项网络决策辅助工具,用于支持面临启动或更换生物制剂或靶向合成改善病情抗风湿药治疗决策的中轴型脊柱关节炎患者。该工具包含咨询支持说明、治疗选择概览、药物详细信息和交互式选项网格以及最终决策支持检查,并已在荷兰多个风湿病诊疗环境中引入临床实践。

要点

  • 开发了基于证据的网络决策辅助工具,支持中轴型脊柱关节炎患者启动或更换b/tsDMARD的共享决策。
  • 工具包含咨询支持说明、治疗选择概览、药物详细信息和交互式选项网格及最终决策检查。
  • 该工具已在荷兰多个风湿病诊疗环境中引入临床实践。

核心结论

  • 开发了一项基于证据的决策辅助工具,以支持面临启动或更换b/tsDMARD治疗决策的中轴型脊柱关节炎患者,并将其引入临床实践。

研究设计与样本

  • 通过迭代过程系统开发决策辅助工具,依据文献证据、患者和照护者的探索性需求评估访谈,以及荷兰风湿病学会脊柱关节炎工作组专家和荷兰关节炎协会患者信息专业人员的意见。

主要发现

  • 决策辅助工具包含咨询支持说明、中轴型脊柱关节炎可用治疗选择概览、b/tsDMARD详细信息和交互式选项网格以及最终决策检查。
  • 风湿病学家在荷兰多个风湿病诊疗环境中引入了该决策辅助工具。
  • 荷兰关节炎协会在其网站、社交媒体和月度通讯上发布了该决策辅助工具。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To develop a web-based evidence-based decision aid to support shared decision-making in patients with axial spondyloarthritis (axSpA) who face a treatment decision to initiate or switch a biological or targeted synthetic disease modifying antirheumatic drug (b/tsDMARDs). METHODS: Through an iterative process, we systematically developed a decision aid based on evidence from the literature, explorative needs assessment interviews among patients and care providers, and input from experts of the SpA working group of the Dutch Society for Rheumatology and professionals on patient information employed at the Dutch Arthritis Society. The usability, ease of use and feasibility of the pilot version were tested among stakeholders and feedback was used to adapt the decision aid. Finally, a multifaceted strategy was used to introduce the decision aid in clinical practice. RESULTS: The decision aid consists of (1) consultation support instructions in the context of disease control and treatment needs, (2) an overview of available treatment options for axSpA, (3) detailed information on b/tsDMARDs and an interactive option grid that facilitates comparison of characteristics and (4) a final check supporting patients to deliberate on the decision to initiate or switch a b/tsDMARD. Rheumatologists introduced the decision aid in several Dutch rheumatology settings and the Dutch Arthritis Society posted it on their website, social media and in their monthly newsletter. CONCLUSION: We developed an evidence-based decision aid to support axSpA patients who face a treatment decision to initiate or switch a b/tsDMARD and introduced this in clinical practice.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Beckers E, Boonen A, van Tubergen A, et al. Development of a web-based decision aid for initiating biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in axial spondyloarthritis. RMD Open. 2023. PMID: 37263741. doi:10.1136/rmdopen-2023-003103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。